#MarksManInsights

As the landscape of healthcare data evolves, computable phenotypes are becoming crucial for the generation and validation of real-world evidence (RWE), especially in regulatory contexts. A computable phenotype is “a clinical condition, characteristic, or set of clinical features that can be determined solely from data in electronic health records (EHRs) and ancillary data sources and does not require chart review or interpretation by a clinician.”(1) Essentially, computable phenotypes are machine-executable, algorithmic definitions used to select patients with specific clinical features, such as conditions, exposures, or outcomes, in large, often cluttered real-world data (RWD) sources like electronic health records (EHRs) and medical claims. These definitions are created from structured data elements, logical expressions, and clinical criteria that facilitate objective, consistent, and reproducible identification of populations appropriate for a study.(1, 2)

Regulatory bodies like the USFDA (3) and EMA (4) increasingly expect RWE adopted in submissions to be transparent and methodologically rigorous. Computable phenotypes are pivotal in this case as they enable replicable cohort selection and outcome determination.(5) Sponsors can offer regulators with a clear, auditable trajectory of selection of patient populations and definition of outcomes by inserting these algorithms directly into study protocols and analysis plans. Such rigorous detailing is especially crucial for studies relying on different data sources with changing formats, coding systems, and clinical granularity.(6-8)

One of the major advantages of computable phenotypes is the consistency they offer to RWE studies. Flexibility of real-world datasets, owing to disparities in healthcare delivery, data capture, or coding practices, can result in bias, thus reducing the dependability of findings. Computable phenotypes help alleviate these risks by applying a common, validated logic across datasets, diminishing the possibility of misclassification and enabling consistency in the application of inclusion and exclusion criteria. Consequently, regulators can evaluate the strength of the evidence with greater confidence.(1, 2, 8)

Computable phenotypes also enhance the evidence generation efficiency. By computerizing the selection of eligible patients, exposures, and clinical endpoints, researchers can simplify study implementation and minimize the dependence on manual chart reviews or case-by-case abstraction. This automation reduces timelines and thus human error, which is particularly important in large-scale or time-sensitive studies. Additionally, this approach is suitable for flexibility, making the replication of analyses across multiple databases or healthcare systems possible, further enabling the assessment of robustness and generalizability.(1, 2, 8)

Despite evident benefits, applying high-quality computable phenotypes has some limitations. The inconsistencies in clinical data, changing terminologies, and varying methods of data capture can make standardization challenging. Moreover, while developing a computable phenotype may be technically feasible, justifying its accuracy across different populations and settings is often resource-demanding; which necessitates cooperation among clinicians, data scientists, informaticians, and regulatory stakeholders.(8-10) Programs like OHDSI (11, 12) and USFDA’s Sentinel Initiative (13) have developed phenotype definitions, but more work is needed to ensure harmonization and broad applicability.

While many computable phenotypes rely on systematized EHR data, such data may fail to entirely capture the clinical details of a patient’s medical record. Machine learning (ML)–enabled natural language processing (NLP) tools, like the open-source Clinical Annotation Research Kit (CLARK),(14) are increasingly being implemented to extract unstructured clinical notes. CLARK facilitates nonexpert users to apply standard ML algorithms by defining features found in text, improving phenotyping accuracy by integrating variables not available in structured data. This standardizes the use of refined phenotyping methods to expand access to richer, more sensitive phenotype algorithms across research settings. Tools like CLARK have shown robust performance in real-world scenarios, including phenotyping paediatric diabetes and non-alcoholic fatty liver disease, and represent a major development in making ML-driven phenotyping more available.(15)

Validation of computable phenotypes is crucial. A well-structured computable phenotype should be transparent and also perform well in recognizing true cases or outcomes. Regulatory guidance now increasingly focuses on the customizability of phenotypes to the research question and their ability to achieve clear, clinically significant results in RWE studies. Intrinsically, sponsors are expected to report the logic, validation status, and limitations of the phenotypes used, allowing for informed review and analysis by regulators.(1, 2, 5)

Computable phenotypes are the methodological pillars of reliable RWE. They decipher messy, heterogeneous RWD into structured, actionable insights to support high-stakes regulatory decisions. With the regulatory science adopting more complex data and evidence frameworks, computable phenotypes will continue to be indispensable in facilitating robust, transparent, and also reproducible RWE that aligns with public health preferences.

Become A Certified HEOR Professional – Enrol yourself here!

References

1. Richesson RL, et al. Electronic Health Records–Based Phenotyping. NIH Pragmatic Trials Collaboratory. [Accessed online on 17^th June 2025]. Available at: https://rethinkingclinicaltrials.org/chapters/conduct/electronic-health-records-based-phenotyping/definitions/
2. Cameron CB. A User’s Guide to Computable Phenotypes. [Accessed online on 17^th June 2025]. Available at: https://dcricollab.dcri.duke.edu/sites/NIHKR/KR/Blake_Users_Guide_to_Computable_Phenotypes.pdf
3. Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products. August 2023. [Accessed online on 17^th June 2025]. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug
4. Real-world evidence framework to support EU regulatory decision-making Report on the experience gained with regulator-led studies from September 2021 to February 2023.
5. Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products – Guidance for Industry. 2024. [Accessed online on 17^th June 2025]. Available at: https://www.fda.gov/media/152503/download
6. Tasker RC. Why Everyone Should Care About “Computable Phenotypes”. Pediatr Crit Care Med. 2017 May;18(5):489-490.
7. Masison J, Lehmann HP, Wan J. Utilization of Computable Phenotypes in Electronic Health Record Research: A Review and Case Study in Atopic Dermatitis. Journal of Investigative Dermatology. 2025; 145(5):1008-1016.
8. Ahmad FS, Ricket IM, Hammill BG, et al. Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE. Circ Cardiovasc Qual Outcomes. 2020; 13(6):e006292.
9. Shah C. Computable Phenotypes for Generating RWE: What Are They and Can They Really Be Standardized and Reused? Value & Outcomes Spotlight. 2022; 8(3):S1.
10. He T, Belouali A, Patricoski J, et al. Trends and opportunities in computable clinical phenotyping: A scoping review. Journal of Biomedical Informatics. 2023; 140:104335.
11. The Observational Health Data Sciences and Informatics (OHDSI). [Accessed online on 17^th June 2025]. Available at: https://www.ohdsi.org
12. Zelko JS, Gasman S, Freeman SR, et al. Developing a Robust Computable Phenotype Definition Workflow to Describe Health and Disease in Observational Health Research. 2023. [Accessed online on 17^th June 2025]. Available at: https://arxiv.org/abs/2304.06504
13. Sentinel Initiative. A General Framework for Developing Computable Clinical Phenotype Algorithms. 2024. [Accessed online on 17^th June 2025]. Available at: https://www.sentinelinitiative.org/news-events/publications-presentations/general-framework-developing-computable-clinical-phenotype
14. Repository for CLARK, the Clinical Annotation Research Kit. 2019. [Accessed online on 17^th June 2025]. Available at: https://github.com/NCTraCSIDSci/clark
15. Pfaff ER, Crosskey M, Morton K, Krishnamurthy A. Clinical Annotation Research Kit (CLARK): Computable Phenotyping Using Machine Learning. JMIR Med Inform 2020; 8(1):e16042.